

BC Cancer Protocol Summary for Second-line Treatment of Recurrent Small Cell Lung Cancer (SCLC) with Topotecan

Protocol Code
Tumour Group
Contact Physician

LUSCTOP
Lung
Dr. Christopher Lee

ELIGIBILITY:

- Recurrent/progressive small cell lung cancer following first-line therapy
- ECOG performance status 0-2
- Relative contraindication to LUSCCAV

EXCLUSIONS:

- ECOG performance status 3-4

TESTS:

- Baseline: CBC & diff (including platelets), sodium, potassium, BUN, creatinine
- Before each treatment: CBC & diff (including platelets), creatinine
- Weekly: CBC & diff (including platelets)

PREMEDICATIONS:

- Antiemetic protocol for Low-Moderate emetogenic chemotherapy (see protocol SCNAUSEA)

TREATMENT:

Drug	Dose	BC Cancer Administration Guideline
topotecan	1.5 mg/m ² /day x 5 days (days 1 to 5)	IV in 50mL NS over 30 minutes

- Repeat 5-day treatment every 21 days x 4-6 cycles

DOSE MODIFICATIONS:

1. Hematology:

a) on treatment day:

ANC (x 10 ⁹ /L)		Platelets (x 10 ⁹ /L)	Dose
greater than or equal to 1.0	and	greater than or equal to 100	treat as per nadir
less than 1.0	or	less than 100	delay until recovery

b) at nadir:

ANC (x 10 ⁹ /L)		Platelets (x 10 ⁹ /L)	Dose
less than 0.5	or	less than 50	decrease by 0.25 mg/m ² /day*

2. **Any Grade 3 or 4 toxicity (except nausea):** decrease dose by 0.25mg/m²/day*

*e.g. if initial dose is 1.5 mg/m²/day x 5 days → 1.25 mg/m²/day x 5 days.
if initial dose is 1.25 mg/m²/day x 5 days → 1.0 mg/m²/day x 5 days.

3. **Renal Dysfunction:**

Creatinine Clearance (mL/min)	Topotecan Dose
greater than or equal to 40	100%
20-39	50%
less than 20	not recommended

$$\text{CrCl (mL/min)} = \frac{N \times (140 - \text{age}) \times \text{weight (kg)}}{\text{serum creatinine } (\mu\text{mol/L)}}$$

where N = 1.04 for females and 1.23 for males

PRECAUTIONS:

1. **Neutropenia:** Fever or other evidence of infection must be assessed promptly and treated aggressively.

Call Dr. Christopher Lee or tumour group delegate at (604) 930-2098 or 1-800-523-2885 with any problems or questions regarding this treatment program.

REFERENCES:

von Pawel J, Schiller JH, Shepherd FA, et al. Topotecan versus cyclophosphamide, doxorubicin and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 1999; 17: 658-667.